340B Drug Pricing Program
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to patient mix changes as a result of the COVID-19 pandemic.
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.
The Supreme Court of the United States today decided to take up AHA’s petition asking to reverse a federal appeals court decision that significantly cuts payments to certain hospitals that participate in the 340B Drug Pricing Program, threatening access to care in communities.
We are pleased that the U.S. Supreme Court has agreed to hear the compelling arguments in our case on payments cuts to the 340B drug pricing program that are adversely impacting care to patients.
Amicus Brief Eli Lilly v Cochran Re 340B Contract Pharmacy – Intervention filed June 23, 2021.
Amicus Brief NOVO NORDISK v Cochran Re 340B Contract Pharmacy – Intervention
HRSA will continue enforcement actions against drug manufacturers and contract pharmacy arrangements
Columbus, Ohio-based Mount Carmel Health System goes beyond the walls of its hospital to serve its community and patients through programs such as Street Medicine, which provides free urgent medical care to underinsured or uninsured individuals. Hear from Mount Carmel’s Brian Pierson, vice…
The AHA 340B Advocacy Alliance Wednesday, June 16, at 2:30 p.m. ET will host a special call for AHA 340B hospital members to provide an update on the latest activity on the 340B Drug Pricing Program.
The 340B program, established by section 340B of the Public Health Service
Act, 42 U.S.C. § 256b, requires as a condition of participating in Medicaid and Medicare Part B that pharmaceutical manufacturers sell outpatient drugs at a discounted price to certain public and not-for-profit hospitals,…